Hub : Traits :

Alcohol intake frequency.

1037 significantly associated models · 181 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 752566 1620860 1 1 6.6e-08 1.4e-07 6.3e-02 88 RP11-54O7.17
2 2 23453834 25040082 3 2 8.0e-10 2.3e-10 2.2e-01 96 PFN4 UBXN2A
3 2 26592429 29260106 19 8 7.6e-28 7.6e-40 NaN NaN AC074117.10 FNDC4 KRTCAP3 NRBP1 RP11-195B17.1 SLC4A1AP
4 2 44448632 45864710 1 1 1.2e-10 4.9e-10 1.0e+00 100 RP11-89K21.1
5 2 100029106 101419887 1 1 3.9e-07 2.3e-05 4.1e-02 77 AC092667.2
6 3 37804853 39280382 2 1 1.9e-07 1.4e-07 1.0e+00 100 ACVR2B
7 3 48757291 50921261 10 6 5.3e-12 2.2e-10 1.0e+00 100 APEH MON1A MST1R RBM6 TCTA
8 3 84317575 86808226 1 1 3.6e-08 2.4e-09 2.2e-02 85 CADM2
9 4 2389800 3961912 2 2 8.0e-08 8.6e-11 6.2e-04 72 C4orf44 HTT
10 4 38491835 40339574 8 1 1.4e-24 1.8e-32 1.0e-09 74 RFC1
11 4 99528449 100942337 1 2 1.1e-18 5.0e-46 1.1e-42 8 ADH1B
12 5 87006055 88429077 1 1 1.2e-14 1.7e-13 8.5e-01 100 CTC-498M16.2
13 7 44170585 45583220 1 1 6.1e-08 4.9e-08 1.8e-01 94 H2AFV
14 7 72674074 74494207 3 2 1.5e-10 5.5e-07 1.9e-01 93 MLXIPL STAG3L2
15 7 98989626 100746658 2 1 2.4e-07 4.4e-06 1.0e+00 100 NYAP1
16 8 142629143 144179460 1 1 2.0e-07 5.9e-09 2.7e-08 9 TSNARE1
17 11 46622392 48485877 9 1 3.1e-13 1.8e-12 3.5e-01 98 C1QTNF4
18 11 64333296 65770658 1 1 6.4e-09 2.0e-08 2.2e-01 95 POLA2
19 12 53926889 55370164 1 1 1.0e-12 1.1e-16 1.8e-05 73 CBX5
20 12 123049746 124449223 1 1 3.4e-08 1.1e-06 4.1e-01 97 CDK2AP1
21 13 49186783 50706551 1 1 3.2e-08 9.0e-09 9.6e-05 54 CAB39L
22 15 77023336 78525994 2 1 6.3e-08 2.7e-07 1.4e-01 92 HMG20A
23 16 27412414 31833122 60 3 3.3e-24 1.9e-21 2.1e-01 98 KAT8 SULT1A2 TBX6
24 16 68681792 70725815 2 2 3.5e-09 2.2e-07 4.0e-02 84 PDXDC2P TMED6
25 16 71227328 72800567 2 1 5.3e-08 7.6e-07 1.2e-01 90 TXNL4B
26 17 6831407 8304086 2 2 3.2e-07 3.9e-07 3.6e-01 97 EFNB3 SAT2
27 17 17400972 18923818 10 1 9.1e-10 8.1e-10 1.0e+00 100 LLGL1
28 17 40009690 41510850 2 1 5.6e-08 6.1e-08 1.0e-01 91 TUBG2
29 17 42774693 45796313 19 1 7.6e-12 1.3e-10 1.0e+00 100 KANSL1
30 17 56950920 58383168 1 1 9.9e-08 1.5e-07 1.1e-01 91 DHX40
31 18 20082830 22415141 4 1 1.8e-19 7.3e-17 9.4e-01 100 NPC1
32 18 52209411 54028036 1 1 1.2e-08 1.3e-08 7.8e-02 90 TCF4
33 19 48464978 49935001 5 1 7.2e-11 1.2e-10 2.5e-01 97 RASIP1
34 20 34828459 36277359 1 1 1.0e-07 1.8e-09 4.1e-04 66 SAMHD1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (in mother) 1.71 1 0 0.0 0.00 1.0e+00 KAT8
Alzheimer’s Disease (including proxy) 1.81 1 1 3.0 0.00 1.0e+00 KAT8
Crohns Disease (2017) 4.40 10 6 18.2 -0.06 8.7e-01 AC074117.10 APEH FNDC4 MON1A MST1R RASIP1 RBM6 SLC4A1AP SULT1A2 TCTA
Irritable Bowel Disease (IBD) 4.16 8 5 15.2 -0.10 7.9e-01 APEH KRTCAP3 MON1A MST1R RBM6 SLC4A1AP STAG3L2 SULT1A2
Ulcerative Colitis (UC) 2.75 5 4 12.1 -0.49 3.2e-01 APEH MON1A MST1R RBM6 SULT1A2
Major Depression (MDD) 2.10 1 0 0.0 0.00 1.0e+00 TCF4
Reaction Time 2.02 1 0 0.0 0.00 1.0e+00 TCTA
Verbal and Numeric Reasoning (VNR) 4.19 7 6 18.2 0.98 1.7e-05 APEH MON1A MST1R RBM6 SULT1A2 TCTA UBXN2A
Breast Cancer 1.18 1 0 0.0 0.00 1.0e+00 KANSL1
Ovarian Cancer 1.71 1 1 3.0 0.00 1.0e+00 KANSL1
Prostate Cancer 1.71 1 0 0.0 0.00 1.0e+00 MON1A
Age at First Birth 4.81 5 5 15.2 0.99 8.4e-05 APEH MON1A MST1R RBM6 TCTA
Body Mass Index (BMI) (2010) 3.16 2 2 6.1 0.00 1.0e+00 C1QTNF4 SULT1A2
Crohns Disease (2012) 3.94 7 2 6.1 0.45 3.1e-01 APEH MON1A MST1R RASIP1 RBM6 SULT1A2 TCTA
Fasting Glucose 6.24 6 6 18.2 0.99 1.6e-05 AC074117.10 FNDC4 KRTCAP3 NRBP1 RP11-195B17.1 SLC4A1AP
HbA1C 1.23 1 0 0.0 0.00 1.0e+00 PFN4
HDL Cholesterol 2.47 2 1 3.0 0.00 1.0e+00 MLXIPL RBM6
LDL Cholesterol 1.47 1 1 3.0 0.00 1.0e+00 RASIP1
Neuroticism 1.71 2 1 3.0 0.00 1.0e+00 C1QTNF4 TCF4
Primary Biliary Cirrhosis 2.10 1 0 0.0 0.00 1.0e+00 KANSL1
Schizophrenia 1.72 2 1 3.0 0.00 1.0e+00 ACVR2B CDK2AP1
Triglycerides 23.05 8 8 24.2 -0.98 1.2e-06 AC074117.10 FNDC4 KAT8 KRTCAP3 MLXIPL NRBP1 RP11-195B17.1 SLC4A1AP
Ulcerative Colitis 2.84 4 1 3.0 0.99 1.3e-02 APEH MON1A MST1R RBM6
Blood Eosinophil Count 1.70 12 7 21.2 -0.05 8.8e-01 APEH CDK2AP1 FNDC4 H2AFV KANSL1 KAT8 MLXIPL MON1A MST1R RBM6 TBX6 TMED6
Blood Platelet Count 5.08 19 16 48.5 -0.53 1.3e-02 AC074117.10 ADH1B C1QTNF4 C4orf44 CBX5 CDK2AP1 DHX40 FNDC4 H2AFV HTT KRTCAP3 MLXIPL NRBP1 NYAP1 PFN4 RASIP1 RP11-195B17.1 SLC4A1AP TBX6
Blood Red Count 3.13 13 12 36.4 -0.27 3.7e-01 CTC-498M16.2 FNDC4 H2AFV KANSL1 KAT8 MST1R PFN4 POLA2 RBM6 RFC1 SULT1A2 TBX6 TCTA
Blood White Count 5.49 25 22 66.7 -0.65 1.6e-04 AC074117.10 APEH C1QTNF4 C4orf44 CTC-498M16.2 DHX40 FNDC4 H2AFV HTT KANSL1 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 NYAP1 PFN4 RBM6 RP11-195B17.1 SLC4A1AP TBX6 TUBG2 UBXN2A
Heel T-Score 2.28 13 9 27.3 -0.25 3.9e-01 APEH C1QTNF4 CDK2AP1 KANSL1 KAT8 MST1R NPC1 NYAP1 RBM6 STAG3L2 TBX6 TCTA TUBG2
BMI 6.79 22 17 51.5 -0.74 6.3e-05 AC092667.2 ACVR2B APEH C1QTNF4 CADM2 CBX5 CTC-498M16.2 FNDC4 H2AFV KAT8 MLXIPL MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TMED6 TUBG2
Height 2.16 29 25 75.8 0.39 3.1e-02 AC074117.10 C1QTNF4 C4orf44 CDK2AP1 EFNB3 FNDC4 HTT KANSL1 KRTCAP3 LLGL1 MLXIPL NPC1 NRBP1 NYAP1 PDXDC2P PFN4 RASIP1 RFC1 RP11-195B17.1 RP11-54O7.17 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCF4 TMED6 TUBG2 TXNL4B UBXN2A
Waist Hip Ratio (WHR) 2.41 8 5 15.2 -0.46 2.5e-01 CDK2AP1 EFNB3 KANSL1 LLGL1 MLXIPL RASIP1 RFC1 TCTA
Systolic Blood Pressure 2.26 9 5 15.2 -0.22 5.4e-01 AC074117.10 C1QTNF4 CADM2 KANSL1 KRTCAP3 NRBP1 RASIP1 RP11-195B17.1 TCTA
Smoking Status 2.22 3 2 6.1 0.00 1.0e+00 CADM2 KANSL1 RP11-89K21.1
Allergy or Eczema 1.73 6 1 3.0 -0.23 6.1e-01 AC074117.10 KRTCAP3 NRBP1 SLC4A1AP SULT1A2 TUBG2
Cardiovascular Disease 3.61 15 7 21.2 -0.79 1.7e-04 AC074117.10 C4orf44 FNDC4 KAT8 KRTCAP3 MLXIPL NPC1 NRBP1 PDXDC2P POLA2 RASIP1 RP11-195B17.1 SLC4A1AP STAG3L2 TCTA
Hypothyroidism (self reported) 1.02 1 1 3.0 0.00 1.0e+00 RASIP1
Respiratory disease 1.49 4 0 0.0 -0.55 3.4e-01 AC092667.2 APEH MON1A RBM6
Type 2 Diabetes (T2D) 5.30 12 3 9.1 0.20 4.7e-01 AC074117.10 APEH C1QTNF4 FNDC4 HMG20A KRTCAP3 MON1A NRBP1 RBM6 RP11-195B17.1 SLC4A1AP TCTA
Lung FEV1/FVC ratio 1.12 6 2 6.1 0.21 6.9e-01 CBX5 KANSL1 KAT8 LLGL1 RASIP1 TBX6
Lung FVC 2.42 9 5 15.2 0.71 3.4e-02 AC092667.2 ACVR2B ADH1B KANSL1 KAT8 MON1A TBX6 TCF4 UBXN2A
Neuroticism 3.25 6 3 9.1 0.61 2.0e-01 C1QTNF4 CADM2 CTC-498M16.2 KANSL1 MON1A TCF4
Chronotype (morning person) 2.12 5 1 3.0 -0.43 4.8e-01 APEH CBX5 MON1A PFN4 TXNL4B
Hair Pigment 0.35 8 6 18.2 -0.85 1.9e-03 AC074117.10 CDK2AP1 KANSL1 KRTCAP3 MLXIPL NRBP1 RP11-195B17.1 SLC4A1AP
Tanning 0.52 8 2 6.1 0.93 2.8e-04 AC074117.10 C1QTNF4 CADM2 FNDC4 KRTCAP3 MLXIPL NRBP1 SLC4A1AP
Hand grip strength (left) 3.02 7 5 15.2 0.00 1.0e+00 ACVR2B C1QTNF4 CADM2 KANSL1 NYAP1 TBX6 TCF4
Number of treatments/medications taken 4.45 6 3 9.1 0.97 2.0e-04 AC074117.10 APEH MON1A MST1R RBM6 STAG3L2
Average weekly spirits intake 1.82 1 0 0.0 0.00 1.0e+00 RASIP1
Sensitivity / hurt feelings 1.86 1 1 3.0 0.00 1.0e+00 KANSL1
Frequency of depressed mood in last 2 weeks 1.82 1 0 0.0 0.00 1.0e+00 KANSL1
Hearing difficulty/problems: Yes 1.30 1 0 0.0 0.00 1.0e+00 C4orf44
Relative age of first facial hair 3.10 3 1 3.0 0.00 1.0e+00 FNDC4 KANSL1 NPC1
Systolic blood pressure, automated reading 2.10 5 1 3.0 0.08 9.0e-01 C1QTNF4 KANSL1 RASIP1 TCTA TSNARE1
Medication: Co-codamol 2.41 2 0 0.0 0.00 1.0e+00 APEH MON1A
Medication: Metformin 3.98 3 1 3.0 0.00 1.0e+00 C1QTNF4 TCTA TUBG2
Impedance of leg (right) 3.29 18 13 39.4 -0.30 2.2e-01 ACVR2B APEH CADM2 CBX5 DHX40 EFNB3 FNDC4 KANSL1 KAT8 LLGL1 MLXIPL MON1A PDXDC2P PFN4 RBM6 STAG3L2 SULT1A2 TBX6
Leg fat-free mass (left) 4.72 23 17 51.5 0.13 5.3e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TUBG2 UBXN2A
Trunk fat percentage 4.95 14 11 33.3 0.87 2.3e-05 APEH C1QTNF4 HMG20A KANSL1 KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 SULT1A2 TBX6 TCTA TUBG2
Hand grip strength (right) 2.75 5 3 9.1 -0.22 7.2e-01 ACVR2B C1QTNF4 KANSL1 NYAP1 TBX6
Fed-up feelings 3.22 6 4 12.1 0.99 1.7e-05 APEH KANSL1 MON1A MST1R PFN4 RBM6
Relative age voice broke 2.90 1 1 3.0 0.00 1.0e+00 KANSL1
Taking other prescription medications 4.08 5 3 9.1 0.97 1.1e-03 APEH MON1A MST1R RBM6 STAG3L2
Age when periods started (menarche) 2.99 6 2 6.1 -0.55 2.6e-01 APEH C1QTNF4 MON1A PDXDC2P STAG3L2 TBX6
Heel bone mineral density (BMD) T-score, automated (left) 2.30 3 3 9.1 1.00 3.4e-04 MST1R RBM6 TCTA
High blood pressure 1.99 4 1 3.0 0.39 6.1e-01 C1QTNF4 KAT8 RASIP1 STAG3L2
Hayfever, allergic rhinitis or eczema 1.93 5 0 0.0 0.73 9.7e-02 AC074117.10 KRTCAP3 NRBP1 SLC4A1AP TUBG2
Sitting height 3.14 16 13 39.4 -0.81 4.6e-05 AC074117.10 C1QTNF4 CDK2AP1 FNDC4 KANSL1 KRTCAP3 MLXIPL NRBP1 PFN4 RASIP1 RP11-195B17.1 RP11-54O7.17 SAMHD1 SLC4A1AP TMED6 UBXN2A
Body mass index (BMI) 7.03 22 15 45.5 0.88 2.9e-08 AC092667.2 APEH C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 H2AFV HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TMED6 TUBG2
Impedance of leg (left) 3.26 18 14 42.4 -0.21 4.0e-01 ACVR2B APEH CADM2 CBX5 CDK2AP1 EFNB3 FNDC4 KANSL1 KAT8 LLGL1 MLXIPL MON1A PDXDC2P PFN4 RBM6 STAG3L2 SULT1A2 TBX6
Leg predicted mass (left) 4.70 21 17 51.5 0.19 4.0e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 MLXIPL MON1A MST1R NPC1 PFN4 RBM6 RP11-195B17.1 SAMHD1 SULT1A2 TBX6 TUBG2 UBXN2A
Trunk fat mass 5.50 15 12 36.4 0.89 3.3e-06 APEH C1QTNF4 CTC-498M16.2 HMG20A KANSL1 KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 SULT1A2 TBX6 TCTA TUBG2
Waist circumference 6.16 18 13 39.4 0.91 4.2e-08 AC092667.2 APEH C1QTNF4 C4orf44 CADM2 CTC-498M16.2 HMG20A KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Number of incorrect matches in round 1.98 2 2 6.1 0.00 1.0e+00 KAT8 TBX6
Past tobacco smoking 2.39 3 2 6.1 0.00 1.0e+00 CADM2 NPC1 RP11-89K21.1
Nervous feelings 2.69 4 3 9.1 -0.33 6.7e-01 CADM2 CTC-498M16.2 KANSL1 TBX6
Frequency of tenseness / restlessness in last 2 weeks 2.84 1 1 3.0 0.00 1.0e+00 KANSL1
Hair/balding pattern: Pattern 2 1.96 1 1 3.0 0.00 1.0e+00 KANSL1
Had menopause 4.56 6 5 15.2 -0.99 2.0e-06 AC074117.10 CDK2AP1 KRTCAP3 NRBP1 RP11-195B17.1 SLC4A1AP
Forced vital capacity (FVC) 2.62 6 4 12.1 -0.94 6.0e-03 AC092667.2 C1QTNF4 KANSL1 KAT8 TMED6 UBXN2A
Heel bone mineral density (BMD) T-score, automated (right) 2.13 3 3 9.1 1.00 6.5e-04 MST1R RBM6 TCTA
Ever unenthusiastic/disinterested for a whole week 1.76 1 0 0.0 0.00 1.0e+00 KANSL1
Qualifications: None of the above 4.25 8 7 21.2 0.96 4.5e-05 APEH CDK2AP1 CTC-498M16.2 MON1A MST1R RBM6 SULT1A2 TSNARE1
Financial difficulties in last 2 years 2.22 1 0 0.0 0.00 1.0e+00 KAT8
Mouth/teeth dental problems 2.13 1 0 0.0 0.00 1.0e+00 RASIP1
Diabetes (self-reported) 4.80 8 2 6.1 0.01 9.7e-01 AC074117.10 APEH MON1A NRBP1 RBM6 RP11-195B17.1 SLC4A1AP TCTA
Medication: Simvastatin 2.54 2 0 0.0 0.00 1.0e+00 FNDC4 RASIP1
Fluid intelligence score 4.49 6 5 15.2 -0.98 1.6e-04 APEH MON1A MST1R RBM6 SULT1A2 TCTA
Illnesses of siblings 2.42 1 1 3.0 0.00 1.0e+00 KAT8
Neuroticism score 3.04 5 3 9.1 -0.47 4.2e-01 C1QTNF4 CADM2 KANSL1 MON1A TCF4
Weight 6.10 22 15 45.5 0.58 4.0e-03 AC074117.10 APEH C1QTNF4 CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 HMG20A KAT8 MLXIPL MON1A MST1R NPC1 PDXDC2P RBM6 SAMHD1 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Impedance of arm (right) 4.85 15 13 39.4 -0.25 3.4e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CTC-498M16.2 FNDC4 KANSL1 KAT8 MLXIPL MON1A MST1R RBM6 STAG3L2 TBX6
Arm fat percentage (right) 5.70 15 11 33.3 0.95 1.2e-08 APEH C1QTNF4 CTC-498M16.2 HMG20A KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Trunk fat-free mass 4.57 23 19 57.6 -0.15 4.7e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 UBXN2A
Hip circumference 5.11 20 14 42.4 0.75 8.8e-05 APEH C1QTNF4 CADM2 CDK2AP1 CTC-498M16.2 EFNB3 HMG20A KAT8 MLXIPL MON1A MST1R NPC1 PDXDC2P POLA2 RASIP1 RBM6 STAG3L2 SULT1A2 TBX6 TUBG2
Time employed in main current job 1.28 1 0 0.0 0.00 1.0e+00 KANSL1
Alcohol intake versus 10 years previously 7.57 11 5 15.2 0.95 2.3e-06 AC074117.10 APEH CBX5 FNDC4 MON1A MST1R RASIP1 RBM6 RFC1 RP11-54O7.17 SLC4A1AP
Worrier / anxious feelings 2.61 4 3 9.1 0.94 6.4e-02 CADM2 KANSL1 TBX6 TCF4
Frequency of tiredness / lethargy in last 2 weeks 2.00 2 0 0.0 0.00 1.0e+00 HTT POLA2
Hair/balding pattern: Pattern 3 2.58 1 1 3.0 0.00 1.0e+00 KANSL1
Number of live births 2.13 2 0 0.0 0.00 1.0e+00 APEH KANSL1
Forced expiratory volume in 1-second (FEV1) 2.66 6 4 12.1 -0.98 7.0e-04 AC092667.2 KANSL1 KAT8 PFN4 TMED6 UBXN2A
Pulse rate 2.34 2 1 3.0 0.00 1.0e+00 FNDC4 TCTA
Noisy workplace 2.10 1 0 0.0 0.00 1.0e+00 CDK2AP1
Qualifications: A levels/AS levels or equivalent 5.64 7 5 15.2 -0.93 7.8e-04 APEH CDK2AP1 MON1A MST1R RBM6 SULT1A2 TCTA
Mouth/teeth dental problems: Dentures 3.64 7 3 9.1 0.59 1.2e-01 APEH CBX5 DHX40 MON1A MST1R RASIP1 RBM6
Medication: Cholesterol lowering 4.01 7 2 6.1 0.75 5.3e-02 AC074117.10 C4orf44 FNDC4 KRTCAP3 NRBP1 RASIP1 TCTA
Forced expiratory volume in 1-second (FEV1), Best measure 2.71 7 5 15.2 -0.95 8.7e-04 AC092667.2 C1QTNF4 KANSL1 KAT8 MST1R TMED6 UBXN2A
Impedance of arm (left) 4.83 14 13 39.4 -0.35 1.9e-01 ACVR2B APEH CADM2 CBX5 CTC-498M16.2 FNDC4 KANSL1 KAT8 MLXIPL MON1A MST1R RBM6 STAG3L2 TBX6
Arm fat mass (right) 6.58 18 14 42.4 0.90 1.5e-07 AC092667.2 APEH C1QTNF4 CADM2 CTC-498M16.2 HMG20A KAT8 MON1A MST1R NPC1 PDXDC2P POLA2 RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Trunk predicted mass 4.56 23 19 57.6 -0.15 4.6e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 UBXN2A
Standing height 2.26 24 19 57.6 -0.43 3.0e-02 AC074117.10 C1QTNF4 C4orf44 CDK2AP1 EFNB3 FNDC4 HTT KANSL1 KRTCAP3 LLGL1 NPC1 NRBP1 PDXDC2P PFN4 RASIP1 RFC1 RP11-195B17.1 RP11-54O7.17 SAMHD1 SLC4A1AP SULT1A2 TBX6 TMED6 UBXN2A
Exposure to tobacco smoke at home 2.16 1 0 0.0 0.00 1.0e+00 MON1A
Tense / 'highly strung' 2.00 2 1 3.0 0.00 1.0e+00 CADM2 KAT8
Seen doctor (GP) for nerves, anxiety, tension or depression 2.14 1 1 3.0 0.00 1.0e+00 TCF4
Hair/balding pattern: Pattern 4 3.01 2 1 3.0 0.00 1.0e+00 CBX5 KANSL1
Birth weight of first child 1.87 1 0 0.0 0.00 1.0e+00 SULT1A2
Peak expiratory flow (PEF) 2.37 3 1 3.0 0.00 1.0e+00 KANSL1 RASIP1 UBXN2A
Ever highly irritable/argumentative for 2 days 2.63 3 1 3.0 -0.12 8.8e-01 APEH MON1A RBM6
Qualifications: O levels/GCSEs or equivalent 2.49 1 1 3.0 0.00 1.0e+00 CDK2AP1
Medication: Paracetamol 2.87 1 1 3.0 0.00 1.0e+00 KANSL1
Headache pain in last month 2.27 1 1 3.0 0.00 1.0e+00 KANSL1
Medication for cholesterol, blood pressure or diabetes 3.11 3 0 0.0 0.00 1.0e+00 MST1R RASIP1 TCTA
Gout (self-reported) 7.94 8 7 21.2 0.81 4.9e-03 AC074117.10 FNDC4 KRTCAP3 MLXIPL NRBP1 RFC1 RP11-195B17.1 SLC4A1AP
Birth weight 1.64 4 0 0.0 -0.56 4.4e-01 ACVR2B PFN4 RASIP1 UBXN2A
Chronic bronchitis/emphysema (mother) 2.36 1 0 0.0 0.00 1.0e+00 MON1A
High blood pressure (siblings) 2.41 2 1 3.0 0.00 1.0e+00 KAT8 RFC1
Forced vital capacity (FVC), Best measure 2.71 7 6 18.2 -0.96 7.4e-04 AC092667.2 C1QTNF4 KANSL1 KAT8 MST1R TMED6 UBXN2A
Body fat percentage 5.49 15 12 36.4 0.89 4.2e-06 APEH C1QTNF4 CTC-498M16.2 HMG20A KANSL1 KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 SULT1A2 TBX6 TCTA TUBG2
Leg fat percentage (right) 5.85 19 13 39.4 0.95 8.4e-11 APEH C1QTNF4 C4orf44 CTC-498M16.2 H2AFV HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P PFN4 RBM6 SULT1A2 TBX6 TCTA TMED6 UBXN2A
Arm fat-free mass (right) 5.50 25 21 63.6 0.05 8.0e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCTA UBXN2A
Exposure to tobacco smoke outside home 2.52 2 0 0.0 0.00 1.0e+00 APEH MON1A
Comparative body size at age 10 3.22 9 5 15.2 0.80 1.0e-02 AC074117.10 C1QTNF4 CADM2 CTC-498M16.2 KAT8 NPC1 RASIP1 SULT1A2 TBX6
Worry too long after embarrassment 1.86 1 0 0.0 0.00 1.0e+00 KANSL1
Wheeze or whistling in the chest in last year 3.49 5 4 12.1 1.00 2.7e-05 APEH KAT8 MON1A MST1R RBM6
Number of children fathered 2.66 1 0 0.0 0.00 1.0e+00 CADM2
Reason for reducing amount of alcohol drunk: Health precaution 2.45 2 0 0.0 0.00 1.0e+00 CTC-498M16.2 RFC1
Age at first live birth 4.24 4 4 12.1 -0.99 7.7e-04 APEH MON1A MST1R RBM6
Shortness of breath walking on level ground 2.10 1 0 0.0 0.00 1.0e+00 NPC1
Qualifications: College or University degree 6.49 14 9 27.3 -0.88 1.2e-05 APEH CBX5 CDK2AP1 CTC-498M16.2 KANSL1 KAT8 MON1A MST1R NPC1 NYAP1 RBM6 SULT1A2 TBX6 UBXN2A
Medication for pain relief, constipation, heartburn 2.80 1 1 3.0 0.00 1.0e+00 KANSL1
Medication: Allopurinol 5.94 8 7 21.2 0.80 5.2e-03 AC074117.10 FNDC4 KRTCAP3 MLXIPL NRBP1 RFC1 RP11-195B17.1 SLC4A1AP
Medication: Seretide 50 evohaler 1.76 1 0 0.0 0.00 1.0e+00 MON1A
Mean time to correctly identify matches 2.07 1 0 0.0 0.00 1.0e+00 TCTA
Whole body fat mass 6.20 16 13 39.4 0.91 5.9e-07 APEH C1QTNF4 CADM2 CTC-498M16.2 HMG20A KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Leg fat mass (right) 6.80 18 13 39.4 0.89 4.3e-07 APEH C1QTNF4 CADM2 CTC-498M16.2 H2AFV HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Arm predicted mass (right) 5.47 25 19 57.6 0.06 7.6e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCTA UBXN2A
Pulse rate, automated reading 4.23 12 7 21.2 0.96 7.4e-09 AC074117.10 CTC-498M16.2 FNDC4 HTT KRTCAP3 MLXIPL MST1R NRBP1 RBM6 RP11-195B17.1 SLC4A1AP TCTA
Comparative height size at age 10 2.63 15 12 36.4 -0.11 6.9e-01 AC074117.10 CDK2AP1 FNDC4 KANSL1 KRTCAP3 NPC1 NRBP1 PFN4 RASIP1 RP11-195B17.1 SAMHD1 SULT1A2 TBX6 TCF4 UBXN2A
Suffer from 'nerves' 2.52 4 3 9.1 0.22 7.8e-01 C1QTNF4 CADM2 CTC-498M16.2 SULT1A2
Overall health rating 4.35 6 5 15.2 0.93 2.5e-03 APEH KAT8 MON1A MST1R NPC1 RBM6
Chest pain or discomfort 2.24 1 0 0.0 0.00 1.0e+00 HTT
Age at last live birth 4.28 4 4 12.1 -1.00 3.1e-04 APEH MON1A MST1R RBM6
Leg pain on walking 2.49 3 2 6.1 0.10 9.0e-01 APEH MON1A RBM6
Qualifications: NVQ or HND or HNC or equivalent 3.10 2 0 0.0 0.00 1.0e+00 MST1R RBM6
Supplements: Vitamin C 1.44 1 0 0.0 0.00 1.0e+00 KANSL1
Knee pain experienced in last month 2.18 3 0 0.0 0.00 1.0e+00 APEH KAT8 RBM6
Hypertension (Self-reported) 2.00 3 2 6.1 0.00 1.0e+00 KAT8 RASIP1 STAG3L2
Smoking status: Previous 2.21 3 1 3.0 0.00 1.0e+00 CADM2 NPC1 RP11-89K21.1
Forced expiratory volume in 1-second (FEV1), predicted 1.32 1 0 0.0 0.00 1.0e+00 LLGL1
Whole body fat-free mass 4.77 25 18 54.5 -0.02 9.4e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 UBXN2A
Leg fat-free mass (right) 4.47 20 17 51.5 0.18 4.1e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 MLXIPL MON1A MST1R NPC1 PFN4 RBM6 SAMHD1 SULT1A2 TBX6 TUBG2 UBXN2A
Arm fat percentage (left) 5.82 17 11 33.3 0.95 1.6e-09 APEH C1QTNF4 C4orf44 CTC-498M16.2 HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Average weekly red wine intake 4.15 4 1 3.0 -0.99 8.2e-03 CADM2 CDK2AP1 CTC-498M16.2 NPC1
Handedness (chirality/laterality): Left-handed 2.12 2 1 3.0 0.00 1.0e+00 KANSL1 SULT1A2
Mood swings 3.82 6 3 9.1 -0.52 2.3e-01 APEH C1QTNF4 KANSL1 MON1A RBM6 TCF4
Loneliness, isolation 2.30 2 1 3.0 0.00 1.0e+00 C1QTNF4 KANSL1
Ever had bowel cancer screening 2.78 1 0 0.0 0.00 1.0e+00 MON1A
Diabetes diagnosed by doctor 5.03 10 3 9.1 -0.29 3.6e-01 AC074117.10 FNDC4 KRTCAP3 NRBP1 PDXDC2P RBM6 RP11-195B17.1 SLC4A1AP TCTA TUBG2
Friendships satisfaction 1.60 1 0 0.0 0.00 1.0e+00 NPC1
Qualifications: nursing, teaching 2.91 5 0 0.0 -0.99 5.6e-04 APEH CDK2AP1 MON1A MST1R RBM6
Mouth/teeth dental problems: Mouth ulcers 2.09 2 1 3.0 0.00 1.0e+00 CDK2AP1 KANSL1
Medication for cholesterol 2.55 2 0 0.0 0.00 1.0e+00 FNDC4 RASIP1
Mineral and other dietary supplements 1.53 1 0 0.0 0.00 1.0e+00 CTC-498M16.2
Smoking status: Current 1.77 1 0 0.0 0.00 1.0e+00 RP11-89K21.1
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.23 3 2 6.1 0.00 1.0e+00 KANSL1 KAT8 TBX6
Whole body water mass 4.85 24 18 54.5 -0.03 8.8e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 UBXN2A
Leg predicted mass (right) 4.48 20 17 51.5 0.18 4.2e-01 AC074117.10 ACVR2B APEH CADM2 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 MLXIPL MON1A MST1R NPC1 PFN4 RBM6 SAMHD1 SULT1A2 TBX6 TUBG2 UBXN2A
Arm fat mass (left) 6.54 16 14 42.4 0.90 8.6e-07 APEH C1QTNF4 CADM2 CTC-498M16.2 HMG20A KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Number of self-reported non-cancer illnesses 3.24 3 0 0.0 0.00 1.0e+00 AC074117.10 RASIP1 STAG3L2
Average weekly champagne plus white wine intake 3.02 2 0 0.0 0.00 1.0e+00 CBX5 KANSL1
Miserableness 3.80 7 6 18.2 0.48 2.3e-01 APEH C1QTNF4 KANSL1 MON1A PFN4 RBM6 TCF4
Guilty feelings 2.30 4 1 3.0 0.51 4.9e-01 C1QTNF4 KANSL1 PFN4 UBXN2A
Medication: Blood pressure 1.90 2 0 0.0 0.00 1.0e+00 KANSL1 RASIP1
High cholesterol (Self-reported) 5.84 8 6 18.2 0.78 8.1e-03 AC074117.10 C4orf44 FNDC4 KRTCAP3 NRBP1 RASIP1 RP11-195B17.1 SLC4A1AP
Medication: Bendroflumethiazide 1.88 1 0 0.0 0.00 1.0e+00 TBX6
Medication: Paracetamol 2.65 1 1 3.0 0.00 1.0e+00 KANSL1
Medication: Atorvastatin 3.74 5 1 3.0 0.77 1.3e-01 AC074117.10 FNDC4 NRBP1 RASIP1 SLC4A1AP
Ever smoked 2.37 3 2 6.1 0.00 1.0e+00 CADM2 NPC1 RP11-89K21.1
Basal metabolic rate 5.13 26 19 57.6 0.12 5.5e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCTA TUBG2 UBXN2A
Leg fat percentage (left) 6.07 17 13 39.4 0.95 9.0e-10 APEH C1QTNF4 C4orf44 CTC-498M16.2 H2AFV HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 SULT1A2 TBX6 TCTA UBXN2A
Arm fat-free mass (left) 5.56 25 18 54.5 0.09 6.5e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCTA UBXN2A
Number of operations (self-reported) 2.51 2 0 0.0 0.00 1.0e+00 APEH MON1A
Average weekly beer plus cider intake 3.78 6 3 9.1 -0.20 6.4e-01 ADH1B APEH MON1A RBM6 RFC1 RP11-89K21.1
Irritability 1.54 2 1 3.0 0.00 1.0e+00 KANSL1 TCF4
Risk taking 2.08 1 1 3.0 0.00 1.0e+00 CADM2
Ever had prostate specific antigen (PSA) test 1.40 1 0 0.0 0.00 1.0e+00 CTC-498M16.2
Fractured/broken bones in last 5 years 1.70 1 0 0.0 0.00 1.0e+00 KANSL1
Diastolic blood pressure, automated reading 2.69 8 6 18.2 1.00 1.1e-09 APEH CDK2AP1 KAT8 MON1A MST1R RBM6 TCTA TSNARE1
Vascular/heart problems diagnosed by doctor 2.15 4 1 3.0 -0.56 4.4e-01 KAT8 RASIP1 STAG3L2 TCTA
Cholesterol lowering medication 3.19 3 1 3.0 0.00 1.0e+00 AC074117.10 FNDC4 RASIP1
Pain experienced in last month 2.60 4 0 0.0 0.48 5.2e-01 APEH MON1A RBM6 SAMHD1
Alcohol drinker status: Previous 2.34 1 0 0.0 0.00 1.0e+00 STAG3L2
Impedance of whole body 4.38 17 14 42.4 -0.26 3.0e-01 ACVR2B APEH CADM2 CBX5 CTC-498M16.2 FNDC4 KANSL1 KAT8 LLGL1 MLXIPL MON1A MST1R PDXDC2P PFN4 RBM6 STAG3L2 TBX6
Leg fat mass (left) 6.94 19 13 39.4 0.89 1.6e-07 APEH C1QTNF4 C4orf44 CADM2 CTC-498M16.2 H2AFV HMG20A HTT KAT8 MON1A MST1R NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TBX6 TCTA TUBG2
Arm predicted mass (left) 5.62 26 18 54.5 0.08 7.0e-01 AC074117.10 ACVR2B APEH CADM2 CBX5 CDK2AP1 CTC-498M16.2 EFNB3 FNDC4 KAT8 KRTCAP3 MLXIPL MON1A MST1R NPC1 NRBP1 PFN4 RASIP1 RBM6 RP11-195B17.1 SAMHD1 SLC4A1AP SULT1A2 TBX6 TCTA UBXN2A

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 28 0.802 2.39
GTEx Adipose Visceral Omentum 23 1.130 2.61
GTEx Adrenal Gland 12 0.824 2.27
GTEx Artery Aorta 33 1.108 2.54
GTEx Artery Coronary 19 1.606 2.77
GTEx Artery Tibial 30 0.798 2.42
GTEx Brain Caudate basal ganglia 7 0.761 2.44
GTEx Brain Cerebellar Hemisphere 15 1.007 2.46
GTEx Brain Cerebellum 18 0.908 2.49
GTEx Brain Cortex 17 1.643 2.87
GTEx Brain Frontal Cortex BA9 10 1.082 2.55
GTEx Brain Hippocampus 6 1.145 2.63
GTEx Brain Hypothalamus 6 1.017 2.59
GTEx Brain Nucleus accumbens basal ganglia 11 1.272 2.61
GTEx Brain Putamen basal ganglia 8 1.282 2.60
GTEx Breast Mammary Tissue 18 0.912 2.70
GTEx Breast Mammary Tissue (Male) 14 1.174 2.39
GTEx Breast Mammary Tissue (Female) 18 1.095 2.60
GTEx Cells EBV-transformed lymphocytes 13 0.914 2.45
GTEx Cells Transformed fibroblasts 34 0.810 2.35
GTEx Colon Sigmoid 13 0.889 2.53
GTEx Colon Transverse 25 1.211 2.53
GTEx Esophagus Gastroesophageal Junction 22 1.522 2.82
GTEx Esophagus Mucosa 38 1.145 2.52
GTEx Esophagus Muscularis 35 1.083 2.54
GTEx Heart Atrial Appendage 14 0.887 2.45
GTEx Heart Left Ventricle 21 1.373 2.65
GTEx Liver 10 1.395 2.38
GTEx Lung 34 1.183 2.56
GTEx Muscle Skeletal 26 0.900 2.37
GTEx Nerve Tibial 32 0.741 2.37
GTEx Ovary 14 1.542 3.12
GTEx Pancreas 14 0.858 2.49
GTEx Pituitary 14 1.256 2.36
GTEx Prostate 12 1.437 2.85
GTEx Skin Not Sun Exposed Suprapubic 28 1.139 2.59
GTEx Skin Sun Exposed Lower leg 36 0.989 2.47
GTEx Small Intestine Terminal Ileum 9 1.952 2.93
GTEx Spleen 15 1.063 2.57
GTEx Stomach 18 1.238 2.72
GTEx Testis 27 0.856 2.42
GTEx Thyroid 31 0.775 2.26
GTEx Uterus 11 1.940 2.67
GTEx Vagina 12 1.890 3.05
GTEx Whole Blood 20 1.004 2.25
METSIM Adipose 24 0.521 2.12
NTR Blood 13 0.541 2.00
ROSMAP Brain Pre-frontal Cortex 42 0.957 2.29
YFS Blood 17 0.368 1.96
CommonMind Brain Pre-frontal Cortex 23 0.428 2.18
TCGA Breast Tumor 5 0.652 2.22
TCGA Breast Normal 13 0.309 1.93
TCGA Ovarian Tumor 13 0.445 2.06
TCGA Prostate Tumor 16 0.463 2.16